# GSK plc (GSK) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/GSK
## Company Profile
- Ticker: GSK
- Exchange: NYSE
- Sector: Vaccines, Biopharma, Gene Therapy, Antibody Drugs, Small Molecule Drugs, Nucleic Acid Drugs
- Location: United Kingdom and listed in the U
- Tags: Vaccines, Gene Therapy, Small Molecule Drugs, Antibody Drugs, Oncology
## Stock Data
- Close: 51.46 USD
- Market cap: 98256174646 USD
- Last updated: 2026-08-05
## Business Overview
### Global Biopharmaceutical Portfolio
GSK is a global biopharmaceutical company operating across Specialty Medicines, Vaccines, and General Medicines. Its commercial portfolio spans HIV, oncology, respiratory and immuno-inflammation, vaccines, and established medicines, supported by a growing late-stage pipeline and externally sourced assets.
### Specialty Medicines
Specialty Medicines are a primary growth engine for GSK. HIV therapies, oncology products, and respiratory and immunology medicines give the company a broad commercial presence across chronic and specialty-care markets.
### Vaccines Franchise
GSK maintains one of the industry’s major vaccine portfolios. Shingrix, meningococcal vaccines, Arexvy, and other established products provide a large commercial base supported by global immunization infrastructure.
### Expanding Late-Stage Pipeline
Recent development activity includes the acquisition of the late-stage non-small cell lung cancer assets Jideytro and neladalkib, regulatory-supporting data for Jemperli in locally advanced rectal cancer, and pivotal evidence for bepirovirsen as a potential functional cure for chronic hepatitis B.
### External Innovation Strategy
GSK supplements internal research through acquisitions, licensing, and partnerships that add differentiated late-stage assets. The addition of Jideytro and neladalkib illustrates the company’s use of business development to strengthen therapeutic areas where it already has commercial and clinical infrastructure.
## Why The Stock Is Moving

As of Aug 5, 2026, GSK was little changed and closed at $51.46. No new same-company headline was identified in the current news window.

## Future Catalysts

- A regulatory decision for neladalkib in non-small cell lung cancer is expected in the second half of 2026.
- Regulatory progress for the Jemperli label expansion in locally advanced rectal cancer will be supported by results from the AZUR-1 study.

## Recent News
- 2026-07-29 09:08 EST — [Cabenuva demonstrates superiority to daily oral therapy in adolescents living with HIV, as ViiV Healthcare highlights new long-acting injectable data at AIDS 2026](https://biopharmsignal.com/news/GSK/cabenuva-demonstrates-superiority-to-daily-oral-therapy-in-adolescents-living-wi-f233257f) — Source: GSK plc
- 2026-07-28 12:05 EST — [GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK](https://biopharmsignal.com/news/GSK/gsk-to-establish-new-flagship-r-d-centre-on-cambridge-biomedical-campus-uk-6f2bb859) — Source: GSK plc
- 2026-07-28 12:00 EST — [GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026](https://biopharmsignal.com/news/GSK/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum-plans-ann-1d427d5e) — Source: GSK plc
- 2026-07-28 11:00 EST — [GSK’s licensor Hansoh Pharma announces positive results from a second phase III trial for Ris-Rez in China](https://biopharmsignal.com/news/GSK/gsk-s-licensor-hansoh-pharma-announces-positive-results-from-a-second-phase-iii--07f96324) — Source: GSK plc
- 2026-07-27 14:55 EST — [ViiV Healthcare’s 2-drug regimen Dovato is as effective as 3-drug regimen Biktarvy in first-of-its-kind head-to-head study in treatment-naïve adults living with HIV](https://biopharmsignal.com/news/GSK/viiv-healthcare-s-2-drug-regimen-dovato-is-as-effective-as-3-drug-regimen-biktar-781cde81) — Source: GSK plc